SYNE3

Across TCGA pan-cancer cohorts, SYNE3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SYNE3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SYNE3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNE3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where SYNE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.810	0.385	<.001	62	view →
PDAC	DFS	Quartile	III,IV	0.968	0.503	.006	9	view →
LUAD	DFS	Median	All	0.726	0.483	.037	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SYNE3–CCRCC (DFS)

Open the CCRCC breakdown →